ClinicalTrials.gg
RecruitingNCT06486909HCP-GlcUpdated Mar 18, 2026

Shunt-dependency After aSAH - Role of Early Hyperglycaemia in CSF and Blood

An observational study in Aneurysm, Ruptured, Hyperglycemia and Hydrocephalus, sponsored by Isabel Hostettler. Recruiting at 3 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Isabel Hostettler · Observational

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to confirm the association of early increased glucose levels in cerebro-spinal fluid (CSF) and ventriculo-peritoneal-shunt (VPS)-dependency also evaluating the influence of blood glucose on VPS dependency in patients suffering from an aneurysmal subarachnoid haemorrhage (aSAH). The main questions we aim to answer are:

  • Is there an association of glucose levels on VPS dependency in patients requiring extra-ventricular-drain (EVD) placement for aSAH?
  • In addition, if there is, what is the influence the course of glucose levels has on VPS dependency?

Glucose levels in CSF and serum will be measured on admission, or in case of CSF, upon EVD placement. Glucose in CSF will then be measured every day until EVD removal together with serum glucose. Follow-up will be conducted in person after 3 and 6 months.

Read the detailed description

Aneurysmal SAH is a haemorrhage into the subarachnoid space associated with high mortality and morbidity. Several factors influence morbidity and therefore outcome after aSAH with HCP being one such factor. Hydrocephalus is a well-known complication after aSAH. It is thought to occur due to arachnoid adhesions as a reaction to the blood in the subarachnoid space, leading to impaired CSF absorption. Hydrocephalus is associated with an increased risk of poor clinical outcome, cognitive disturbance, and decreased functional status[3-5]. As such, HCP is associated with a significant increase in morbidity and mortality in aSAH patients and warrants treatment, preferably early. In acute HCP, diversion of CSF is conducted via insertion of an EVD. Due to the blood in the CSF, a permanent system, such as a VPS, is not inserted in the early stages as it would get blocked due to clots. If patients cannot be weaned from the EVD due to persisting HCP a VPS, is then inserted if the CSF is not too bloody anymore. Incidence of aSAH-associated HCP is up to 67%, of which about 50% end up needing a VPS. Several risk factors (ie. increased age, female sex, rebleeding, intraventricular haemorrhage, Fisher grade, and Hunt and Hess grade) have been reported. One factor, especially interesting due to its potential target as a treatment option, is hyperglycaemia. Hyperglycaemia after aSAH is common and most likely due to humeral activation including catecholamine release altering homeostasis. Previous studies have reported an association between hyperglycaemia and VPS dependency. The pathophysiological mechanism behind this potential association remains unclear but is likely due to it adhesions caused by hyperglycaemia and therefore reduction of CSF outflow potentially through higher viscosity. Inflammation, disruption of immune function and disruption of endothelial function might also play a role by decreasing reabsorption. The aim of this study is to evaluate the association of glucose levels in CSF, as well as serum (as CSF glucose is proportional to blood glucose), at prespecified time points and its association with VPS dependency in patients requiring EVD. In this step, timing of VPS insertion is going to be conducted as per our standard. Assessment of early (without trying out repeated weaning) versus late VPS insertion will only be evaluated once the association has been proven in our study.

02

Conditions studied

  • Aneurysm, Ruptured
  • Hyperglycemia
  • Hydrocephalus

Keywords

  • aneurysmal subarachnoid haemorrhage
  • hyperglycaemia
  • hydrocephalus
  • ventriculo-peritoneal shunt
  • extra-ventricular drain
03

In context

Aneurysm, Ruptured

29 studies on the registry are indexed under Aneurysm, Ruptured; 7 are open to participants now.

This study's planned enrollment of 160 is below the median of 183 across 12 observational studies indexed under Aneurysm, Ruptured.

Browse Aneurysm, Ruptured studies →

Lead sponsor

This is the only study on the registry with Isabel Hostettler as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted with aneurysmal subarachnoid haemorrhage

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old and older
  • Hospital admission due to an aneurysmal subarachnoid haemorrhage (radiological confirmation needed)

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years old
  • Non-aneurysmal subarachnoid haemorrhage (eg. trauma, perimesencephalic subarachnoid haemorrhage, mycotic or flow-associated aneurysms)
  • Previous enrolment into the current study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • aSAH Patients

    Patients with an acute ruptured intracranial aneurysm.

    Diagnostic Test: Cerebrospinal Fluid (CSF) Sample · Diagnostic Test: Blood Serum Sample

Interventions

  • Diagnostic testCerebrospinal Fluid (CSF) Sample

    Samples for glucose in CSF will be taken upon EVD/LD placement until EVD/LD removal (within the first 14 days).

  • Diagnostic testBlood Serum Sample

    Samples for glucose in blood serum will be completed every day, for the first 14 days.

06

What researchers measure

Primary outcomes

  1. Ventriculo-peritoneal shunt (VPS) dependency

    Glucose levels in patients requiring EVD/LD placement for aSAH and its influence on VPS dependency.

    Time frame: 6 months

Secondary outcomes

  1. Modified Ranking Scale (mRS)

    Modified Ranking Scale 0-6 where 0 means no symptoms and 6 death (adjusting for VPS dependency) in aSAH patients requiring EVD/LD placement

    Time frame: 6 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Mar 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 5, 2024
StartActual
Mar 26, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2028
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06486909
Lead sponsor
Isabel Hostettler
Collaborators
Kantonsspital Aarau, University Hospital, Basel, Switzerland
Responsible party
Isabel Hostettler (PD Dr. med. Isabel Charlotte Hostettler, PhD, Cantonal Hospital of St. Gallen) — Sponsor-investigator
First posted
Jul 5, 2024
Start date
Mar 26, 2024
Primary completion
Mar 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Mar 18, 2026

Study contacts

Isabel Hostettler, MD PhD
Contact
isabel.hostettler@kssg.ch
+41 71 494 97 40
Lauren Wiebe, BSN MSc
Contact
lauren.wiebe@kssg.ch
Isabel Hostettler, MD PhD
principal investigator · Cantonal Hospital of St. Gallen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion